Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non-Current Debt (2021 - 2026)

Centessa Pharmaceuticals has reported Non-Current Debt over the past 5 years, most recently at $110.1 million for Q4 2025.

  • Quarterly Non-Current Debt rose 1.06% to $110.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110.1 million through Dec 2025, up 1.06% year-over-year, with the annual reading at $110.1 million for FY2025, 1.06% up from the prior year.
  • Non-Current Debt was $110.1 million for Q4 2025 at Centessa Pharmaceuticals, roughly flat from $109.8 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $110.1 million in Q4 2025 and troughed at $67.4 million in Q2 2022.
  • The 5-year median for Non-Current Debt is $75.7 million (2021), against an average of $83.9 million.
  • Year-over-year, Non-Current Debt decreased 7.79% in 2022 and then soared 45.07% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $75.7 million in 2021, then dropped by 7.79% to $69.8 million in 2022, then grew by 8.45% to $75.7 million in 2023, then skyrocketed by 43.91% to $108.9 million in 2024, then grew by 1.06% to $110.1 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Non-Current Debt are $110.1 million (Q4 2025), $109.8 million (Q3 2025), and $109.5 million (Q2 2025).